BR0008182A - Antagonistas do fator de necrose tumoral e seu uso em endometriose - Google Patents

Antagonistas do fator de necrose tumoral e seu uso em endometriose

Info

Publication number
BR0008182A
BR0008182A BR0008182-5A BR0008182A BR0008182A BR 0008182 A BR0008182 A BR 0008182A BR 0008182 A BR0008182 A BR 0008182A BR 0008182 A BR0008182 A BR 0008182A
Authority
BR
Brazil
Prior art keywords
antagonists
endometriosis
necrosis factor
tumor necrosis
factor antagonists
Prior art date
Application number
BR0008182-5A
Other languages
English (en)
Inventor
Francesco Borrelli
Mauro D Antonio
Fabrizio Martelli
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8237393&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0008182(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of BR0008182A publication Critical patent/BR0008182A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Patente de Invenção: "ANTAGONISTAS DO FATOR DE NECROSE TUMORAL E SEU USO EM ENDOMETRIOSE". Antagonistas do fator de necrose tumoral são administrados em doses terapeuticamente eficazes para tratar e/ou prevenir a endometriose. Os antagonistas desta invenção são tipicamente selecionados entre várias classes de moléculas mas de preferência são receptores de TNF solúveis. Os antagonistas são úteis para a regressão de lesões endometriais e, se combinados com outros ingredientes ativos, para melhorar distúrbios relacionados, tal como infertilidade.
BR0008182-5A 1999-01-22 2000-01-19 Antagonistas do fator de necrose tumoral e seu uso em endometriose BR0008182A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99101194A EP1022027A1 (en) 1999-01-22 1999-01-22 Tumor necrosis factor antagonists and their use in endometriosis
PCT/IB2000/000052 WO2000043031A1 (en) 1999-01-22 2000-01-19 Tumor necrosis factor antagonists and their use in endometriosis

Publications (1)

Publication Number Publication Date
BR0008182A true BR0008182A (pt) 2001-11-06

Family

ID=8237393

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0008182-5A BR0008182A (pt) 1999-01-22 2000-01-19 Antagonistas do fator de necrose tumoral e seu uso em endometriose

Country Status (30)

Country Link
US (2) US6663865B1 (pt)
EP (2) EP1022027A1 (pt)
JP (1) JP4601176B2 (pt)
KR (2) KR20060128056A (pt)
CN (2) CN100594932C (pt)
AR (1) AR022251A1 (pt)
AT (1) ATE242002T1 (pt)
AU (1) AU771964B2 (pt)
BG (1) BG65556B1 (pt)
BR (1) BR0008182A (pt)
CA (1) CA2356737C (pt)
CZ (1) CZ302866B6 (pt)
DE (1) DE60003152T2 (pt)
DK (1) DK1143997T3 (pt)
EA (1) EA003927B1 (pt)
EE (1) EE05543B1 (pt)
ES (1) ES2200808T3 (pt)
HK (1) HK1043059B (pt)
HU (1) HU226149B1 (pt)
IL (2) IL144413A0 (pt)
NO (1) NO328814B1 (pt)
NZ (1) NZ512585A (pt)
PL (1) PL204713B1 (pt)
PT (1) PT1143997E (pt)
SI (1) SI1143997T1 (pt)
SK (1) SK287313B6 (pt)
TR (1) TR200102107T2 (pt)
UA (1) UA78483C2 (pt)
WO (1) WO2000043031A1 (pt)
ZA (1) ZA200105263B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU229164B1 (en) * 2001-01-29 2013-09-30 Serono Sa Coinsins Lab Use of il-18 inhibitors for the treatment and/or prevention of heart disease
US20050271663A1 (en) * 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
EP1709965A3 (en) 2001-07-11 2006-12-27 Boehringer Ingelheim Pharmaceuticals, Inc. Methods of treating cytokine mediate diseases
US7082134B1 (en) * 2002-01-18 2006-07-25 Juniper Networks, Inc. Redirect checking in a network device
US20070298041A1 (en) * 2002-06-28 2007-12-27 Tomlinson Ian M Ligands That Enhance Endogenous Compounds
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
DE60325275D1 (de) * 2003-02-07 2009-01-22 Austria Wirtschaftsservice Gmbh Verwendung des menschlichen choriongonadotropins in der behandlung von endometriose-symptomen
US7749999B2 (en) 2003-09-11 2010-07-06 Itherx Pharmaceuticals, Inc. Alpha-ketoamides and derivatives thereof
GB0327112D0 (en) 2003-11-21 2003-12-24 Clincial Designs Ltd Dispenser and reservoir
GB0408449D0 (en) 2004-04-15 2004-05-19 Banerjee Subhasis Diagnostic and therapeutic applications of soluble lhcge protein
AU2005249504A1 (en) * 2004-05-28 2005-12-15 Laboratoires Serono Sa Use of IL-17 in the treatment of fertility-related disorders
US20060045902A1 (en) * 2004-09-01 2006-03-02 Serbousek Jon C Polymeric wrap for in vivo delivery of osteoinductive formulations
CN101282646B (zh) * 2005-07-12 2013-03-27 Dmi生物科学公司 治疗疾病的方法和产品
WO2008149147A2 (en) * 2007-06-06 2008-12-11 Domantis Limited Polypeptides, antibody variable domains and antagonists
ES2523769T3 (es) 2009-06-22 2014-12-01 Ampio Pharmaceuticals, Inc. Procedimiento de tratamiento de enfermedades
SG177302A1 (en) * 2009-06-22 2012-02-28 Dmi Acquisition Corp Methods and products for treatment of diseases
EP2934546A4 (en) 2012-12-19 2016-06-22 Ampio Pharmaceuticals Inc METHOD OF DISEASE TREATMENT
EP3265107B1 (en) 2015-03-02 2024-10-02 180 Therapeutics LP Method of treating a localized fibrotic disorder using a tnf receptor 2 antagonist

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5037805A (en) * 1989-03-20 1991-08-06 The Salk Institute For Biological Studies Methods of contraception
EP1097945B1 (en) * 1991-03-18 2007-07-04 New York University Monoclonal and chimeric antibody specific for human tumor necrosis factor
US20040120952A1 (en) * 2000-08-07 2004-06-24 Centocor, Inc Anti-TNF antibodies and peptides of human tumor necrosis factor
KR100232688B1 (ko) * 1992-09-15 1999-12-01 스코트 쥐. 홀퀴스트 종양 괴사 인자 길항제를 함유하는 tnf-의존성 염증 치료용 제약 조성물
US5389657A (en) * 1993-02-01 1995-02-14 Free Radical Sciences Corporation Method for treating infertility
IL111125A0 (en) * 1994-05-11 1994-12-29 Yeda Res & Dev Soluble oligomeric tnf/ngf super family ligand receptors and their use
US5747532A (en) * 1995-11-21 1998-05-05 Medinox, Inc. Combinational therapeutic methods employing nitric oxide scavengers and compositions useful therefor
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US5710247A (en) * 1996-03-19 1998-01-20 Abbott Laboratories Process and intermediates for the synthesis of LHRH antagonists
GB9607120D0 (en) * 1996-04-04 1996-06-12 Chiroscience Ltd Compounds
GB9616643D0 (en) * 1996-08-08 1996-09-25 Chiroscience Ltd Compounds
ES2326347T3 (es) * 1996-11-27 2009-10-07 Immunex Corporation Metodo para regular la produccion de oxido nitrico.
US6514977B1 (en) * 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors

Also Published As

Publication number Publication date
HK1043059B (zh) 2005-11-18
KR20060128056A (ko) 2006-12-13
NZ512585A (en) 2003-08-29
ZA200105263B (en) 2002-06-26
CA2356737A1 (en) 2000-07-27
KR20010101397A (ko) 2001-11-14
CN1337883A (zh) 2002-02-27
EE200100378A (et) 2002-10-15
AU1997300A (en) 2000-08-07
KR100685106B1 (ko) 2007-02-22
PL350002A1 (en) 2002-10-21
DE60003152T2 (de) 2004-03-25
CN1698894A (zh) 2005-11-23
SK10292001A3 (sk) 2001-12-03
DE60003152D1 (de) 2003-07-10
EA003927B1 (ru) 2003-10-30
NO20013577D0 (no) 2001-07-19
JP4601176B2 (ja) 2010-12-22
HUP0105103A2 (hu) 2002-04-29
BG65556B1 (bg) 2008-12-30
CZ20012656A3 (cs) 2002-02-13
SK287313B6 (sk) 2010-06-07
IL144413A (en) 2009-05-04
HK1043059A1 (en) 2002-09-06
CN1212152C (zh) 2005-07-27
CN100594932C (zh) 2010-03-24
EP1143997B1 (en) 2003-06-04
SI1143997T1 (en) 2003-12-31
TR200102107T2 (tr) 2001-12-21
EP1143997A1 (en) 2001-10-17
JP2002535284A (ja) 2002-10-22
EP1022027A1 (en) 2000-07-26
HUP0105103A3 (en) 2004-08-30
US6663865B1 (en) 2003-12-16
US20040057954A1 (en) 2004-03-25
ES2200808T3 (es) 2004-03-16
EA200100799A1 (ru) 2001-12-24
WO2000043031A1 (en) 2000-07-27
AR022251A1 (es) 2002-09-04
NO20013577L (no) 2001-08-29
NO328814B1 (no) 2010-05-18
PL204713B1 (pl) 2010-02-26
DK1143997T3 (da) 2003-09-15
IL144413A0 (en) 2002-05-23
HU226149B1 (en) 2008-05-28
EE05543B1 (et) 2012-06-15
AU771964B2 (en) 2004-04-08
CZ302866B6 (cs) 2011-12-21
CA2356737C (en) 2010-03-23
PT1143997E (pt) 2003-10-31
ATE242002T1 (de) 2003-06-15
HK1082690A1 (zh) 2006-06-16
UA78483C2 (en) 2007-04-10
BG105691A (en) 2002-02-28

Similar Documents

Publication Publication Date Title
BR0008182A (pt) Antagonistas do fator de necrose tumoral e seu uso em endometriose
EA200400337A1 (ru) Применение модулятора рецепторов глюкокортикоидов и агониста рецепторов глюкокортикоидов при получении лекарственного средства
EP1023315A4 (en) METHODS AND PREPARATIONS FOR DESTRUCTING SPECIFIC PROTEINS
EA200400488A1 (ru) Бензамид и гетероариламид в качестве антагонистов рецептора p2x
BR9911621A (pt) Bifenil sulfonamidas como antagonista duplos de receptor de angiotensina endotelina
TR199901417T2 (xx) Analjezik etkisi olan yeni bile�imler.
BR0107683A (pt) Drospirenona para terapia de reposição de hormÈnio
ATE251140T1 (de) N-(2 oxoacetyl oder sulphonyl)- pyrrolidine/piperidine-2-carbonsäurederivate mit verbesserter multi-drug resistenz aktivität
AU2304300A (en) Indole derivatives and their use as mcp-1 receptor antagonists
BRPI0411699A (pt) compostos para uso como substáncia terapeuticamente ativa; método para o tratamento e/ou profilaxia de doenças que estão associadas à modulação de receptores cb1 e uso destes compostos
BR9507073A (pt) Composto processos para preparar o mesmo e para tratar uma doença no sistema nervoso central composiçao farmacêutica e uso do composto
CA2360313A1 (en) Glucocorticoid receptor modulators
NO20031323D0 (no) Peptid-baserte forbindelser
BR0208533A (pt) Derivados de sapogenina, sìntese e uso dos mesmos e processos com base em seu uso
EA200400689A1 (ru) Фармацевтические и косметические композиции, содержащие ароматические альдегиды, содержащие оксигруппу
BR9811094A (pt) Agente terapêutico para tumores linfáticos
EA200600817A1 (ru) Антагонисты в1 рецептора брадикинина (варианты), фармацевтическая композиция, лекарственное средство, способ лечения заболеваний (варианты)
ATE334139T1 (de) 17 beta-nitro-11 beta-arylsteroide und deren derivate mit hormonalen agonist- oder antagonisteigenschaften
EA200100828A1 (ru) 16-гидроксиэстратриены в качестве эстрогенов избирательного действия
SE9603480D0 (sv) Beredningsform för svårlösliga läkemedel
BRPI0410739A (pt) composição farmacêutica compreendendo um antagonista do receptor p2x7 e um fator de necrose tumoral (alfa)
BRPI0411354A (pt) composições farmacêuticas de atorvastatina, forma de dosagem unitária, métodos para preparar uma composição farmacêutica granulada e para preparar uma forma de dosagem unitária, uso da composição farmacêutica e respectivo kit
MXPA05009135A (es) Formulaciones liquidas de las proteinas de union del factor necrosis del tumor.
Safieh-Garabedian et al. The role of cytokines and prostaglandin-E2 in thymulin induced hyperalgesia
ATE277639T1 (de) Zusammensetzungen von adenosin a1 agonisten und 5ht3 agonisten

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: LABORATOIRES SERONO S.A. (CH)

Free format text: TRANSFERIDO DE: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O C/C 11 E 13 DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.